>
Interpace Biosciences Inc logo

IDXG - Interpace Biosciences Inc Share Price

$8.3 0.6  7.4%

Last Trade - 09/04/21

Sector
Healthcare
Size
Micro Cap
Market Cap £24.9m
Enterprise Value £23.1m
Revenue £23.6m
Position in Universe 5894th / 6827
Bullish
Bearish
Unlock IDXG Revenue
Momentum
Relative Strength (%)
1m +62.2%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -2.35%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
9.43 13.1 15.9 21.9 24.2 32.4 46.8 69.2 +28.0%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020,Interpace Biosciences Inc revenues increased 34% to $32.4M.Net loss applicable to common stockholders excludingextraordinary items increased 8% to $30.1M. Revenuesreflect an increase in demand for the Company's productsand services due to favorable market conditions. Higher netloss reflects Selling/General/Admin. Exp increase of 45% to$20.8M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

IDXG Revenue Unlock IDXG Revenue

Net Income

IDXG Net Income Unlock IDXG Revenue

Normalised EPS

IDXG Normalised EPS Unlock IDXG Revenue

PE Ratio Range

IDXG PE Ratio Range Unlock IDXG Revenue

Dividend Yield Range

IDXG Dividend Yield Range Unlock IDXG Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
IDXG EPS Forecasts Unlock IDXG Revenue
Profile Summary

Interpace Biosciences, Inc., formerly Interpace Diagnostics Group, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, it provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated February 10, 1998
Public Since May 19, 1998
No. of Shareholders: 194
No. of Employees: 152
Sector Healthcare
Industry Healthcare Providers & Services
Index
Exchange Pink Sheets on Nasdaq
Shares in Issue 4,112,055
Free Float (0.0%)
Eligible for
× ISAs
SIPPs
IDXG Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for IDXG
Upcoming Events for IDXG
Friday 9th July, 2021 Estimate
Interpace Biosciences Inc Annual Shareholders Meeting
Frequently Asked Questions for Interpace Biosciences Inc
What is the Interpace Biosciences Inc share price?

As of 09/04/21, shares in Interpace Biosciences Inc are trading at $8.3, giving the company a market capitalisation of £24.9m. This share price information is delayed by 15 minutes.

How has the Interpace Biosciences Inc share price performed this year?

Shares in Interpace Biosciences Inc are currently trading at $8.3 and the price has moved by 77.73% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Interpace Biosciences Inc price has moved by 18.83% over the past year.

What are the analyst and broker recommendations for Interpace Biosciences Inc?

Of the analysts with advisory recommendations for Interpace Biosciences Inc, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Interpace Biosciences Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Interpace Biosciences Inc next release its financial results?

Interpace Biosciences Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Interpace Biosciences Inc dividend yield?

Interpace Biosciences Inc does not currently pay a dividend.

Does Interpace Biosciences Inc pay a dividend?

Interpace Biosciences Inc does not currently pay a dividend.

When does Interpace Biosciences Inc next pay dividends?

Interpace Biosciences Inc does not currently pay a dividend.

How do I buy Interpace Biosciences Inc shares?

To buy shares in Interpace Biosciences Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Interpace Biosciences Inc?

Shares in Interpace Biosciences Inc are currently trading at $8.3, giving the company a market capitalisation of £24.9m.

Where are Interpace Biosciences Inc shares listed? Where are Interpace Biosciences Inc shares listed?

Here are the trading details for Interpace Biosciences Inc:

Country of listing: United States
Exchange: PNK
Ticker Symbol: IDXG
What kind of share is Interpace Biosciences Inc?

Based on an overall assessment of its quality, value and momentum, Interpace Biosciences Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Interpace Biosciences Inc share price forecast 2021?

Shares in Interpace Biosciences Inc are currently priced at $8.3. At that level they are trading at 8.43% discount to the analyst consensus target price of 0.00.

Analysts covering Interpace Biosciences Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.11 for the next financial year.

How can I tell whether the Interpace Biosciences Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Interpace Biosciences Inc. Over the past six months, the relative strength of its shares against the market has been 0.131k%. At the current price of $8.3, shares in Interpace Biosciences Inc are trading at 97.13% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Interpace Biosciences Inc PE Ratio?

We were not able to find PE ratio data for Interpace Biosciences Inc.

Who are the key directors of Interpace Biosciences Inc?

Interpace Biosciences Inc's management team is headed by:

Stephen Sullivan - CHM
Joseph Keegan - IND
Thomas Freeburg - CFO
Eric Lev - NED
Fortunato Rocca - IND
Robert Gorman - DRC
Edward Chan - DRC
Thomas Burnell - PRE
Who are the major shareholders of Interpace Biosciences Inc?

Here are the top five shareholders of Interpace Biosciences Inc based on the size of their shareholding:

Kamin (Peter H) Individual Investor
Percentage owned: 19.02% (782k shares)
Burnell (Thomas W. Ph.D.) Individual Investor
Percentage owned: 5.47% (225k shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 2.85% (117k shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 1.96% (80.6k shares)
Stover (Jack E) Individual Investor
Percentage owned: 1.03% (42.3k shares)
Similar to IDXG
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.